Carcinoid Syndrome
📧 Sign up to get email alerts when something new happens for Carcinoid Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms [Phase 3]
Phase 3 trial update on telotristat etiprate showing expanded treatment for patients with carcinoid syndrome symptoms; results completed wit…
-
FDA approval · 2019-09-05FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for octreotide acetate submitted by Mylan Institutional LLC (ANDA079198). This action constitutes a …
-
FDA approval · 2019-04-11FDA Approved: SANDOSTATIN — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Sandostatin (octreotide acetate) from Novartis Pharmaceuticals Corporation under NDA 019667.
-
CLINICAL_TRIALS trial_result · 2018-12-26Clinical Trial Update: Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy [Phase 2]
Phase 2 trial evaluating telotristat etiprate (LX1606) for symptomatic carcinoid syndrome not controlled by stable-dose octreotide; study co…
-
FDA label_change · 2018-08-27FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Octreotide Acetate submitted by Hikma Pharmaceuticals USA Inc., updating the product labelin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-08-27FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Octreotide acetate from Hikma Pharmaceuticals USA.
-
CLINICAL_TRIALS trial_result · 2018-04-25Clinical Trial Update: A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects [Phase 1]
Phase 1 study evaluating whether omeprazole and famotidine affect the absorption of telotristat ethyl in healthy subjects; the study is comp…
-
CLINICAL_TRIALS trial_result · 2018-04-06Clinical Trial Update: Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome [Phase 2]
Phase 2 trial of telotristat etiprate (LX1606) in symptomatic carcinoid syndrome completed; results posted in 2018.
-
FDA approval · 2018-03-09FDA Approved: OCTREOTIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for octreotide acetate from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2017-09-25Clinical Trial Update: Telotristat Etiprate for Carcinoid Syndrome Therapy [Phase 3]
A Phase 3 trial evaluating Telotristat Etiprate for carcinoid syndrome has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2017-09-18Clinical Trial Update: TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) [Phase 3]
Phase 3 TELESTAR trial evaluating telotristat etiprate for carcinoid syndrome completed with results posted in 2017.
-
FDA approval · 2017-07-10FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Sagent Pharmaceuticals)
FDA approves a supplemental application for Octreotide Acetate submitted by Sagent Pharmaceuticals.
-
FDA approval · 2017-06-27FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Meitheal Pharmaceuticals, Inc.)
The FDA approved Meitheal Pharmaceuticals' supplemental application for octreotide acetate. This approval authorizes a generic octreotide ac…
-
FDA approval · 2017-02-28FDA Approved: XERMELO — Original Application (Lexicon Pharmaceuticals, Inc.)
FDA approved XERMELO (telotristat ethyl) from Lexicon Pharmaceuticals as the original NDA (NDA 208794) for reducing bowel movements in adult…
-
FDA approval · 2016-07-22FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) by Novartis Pharmaceuticals Corporation, resulting in…
-
FDA approval · 2016-05-20FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) by Novartis, resulting in changes to the product …
-
CLINICAL_TRIALS trial_result · 2016-02-09Clinical Trial Update: An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome [Phase 3]
Phase 3 trial evaluating efficacy and safety of Somatuline Depot (lanreotide) for carcinoid syndrome has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2015-09-07Clinical Trial Update: Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome [Phase 2]
Phase 2 trial assessing different doses of BIM 23A760 in carcinoid syndrome was terminated with results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-01-12Clinical Trial Update: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome [Phase 2]
A Phase 2 trial of above-label octreotide LAR for insufficiently controlled carcinoid syndrome in neuroendocrine carcinoma was terminated, w…
-
FDA approval · 2014-01-30FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) submitted by Novartis Pharmaceuticals Corporation. Th…
-
FDA approval · 2013-11-12FDA Approved: OCTREOTIDE ACETATE — Original Application (Sagent Pharmaceuticals)
FDA approved Sagent Pharmaceuticals' generic octreotide acetate (OCTREOTIDE ACETATE) through an Original Application (ANDA).
-
CLINICAL_TRIALS research · 2013-10-29Clinical Trial Update: Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
A clinical trial update discusses a disease-specific questionnaire used to assess quality of life in patients with gastrointestinal-related …
-
CLINICAL_TRIALS trial_result · 2013-10-23Clinical Trial Update: An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males [Phase 1]
Open-label Phase 1 study assessing absorption, metabolism, and excretion of radiolabeled telotristat etiprate in male participants with carc…
-
CLINICAL_TRIALS trial_result · 2013-09-20Clinical Trial Update: Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome [Phase 1, Phase 2]
The document reports pharmacokinetics, efficacy and safety results from phase 1/2 studies of an octreotide implant in patients with carcinoi…
-
CLINICAL_TRIALS trial_result · 2013-07-30Clinical Trial Update: Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease [Phase 3]
Phase 3 trial comparing pasireotide long-acting release to octreotide long-acting release in patients with metastatic carcinoid disease; the…